CHRONIC PROGRESSIVE NEPHROPATHIES IN ELDERLY PATIENTS


Cite item

Full Text

Abstract

The features of course of chronic progressive kidney disease in elderly and senile patients are presented.

About the authors

- -

References

  1. Чеботарев Д.Ф. Особенности заболевания почек в пожилом и старческом возрасте. В кн. Е.М. Тареев (ред.). Основы нефрологии. М., 1972: 816-831.
  2. Борисов И.А., Давыдов В.М., Перов Ю.Л. и др. Структура патологии старческой почки и трудности ее диагностики. Тер. архив. 1986; 8: 37-45.
  3. Хирманов В.Н. Ишемическая болезнь почек. Тер. архив 2001; 6: 61-64.
  4. Moorthy A.V., Zimmerman S.W. Renal disease in the elderly: Clinicopathologic analysis of renal disease in 115 elderly patients. Clin. Nephrol. 1980; 14: 223-229.
  5. Ruggenenti P., Schieppati A., Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357: 1601-1608.
  6. Тареев Е.М. Гломерулонефриты. В: Тареев Е.М. (ред.) Клиническая нефрология. М.; 1983.
  7. Pascual J., Liano F., Ortuno J. The elderly patient with acute renal failure. J. Am. Soc. Nephrol. 1995; 6: 144-153.
  8. Klouche K., Cristol J.P., Kaaki M. et al. Prognosis of acute renal failure in the elderly. Nephrol. Dial. Transplant. 1995; 10: 2240-2243.
  9. Борисов И.А., Михайлова Н.А., Сура В.В. и др. Острая почечная недостаточность у лиц пожилого и старческого возраста. Тер. архив. 1987; 8: 121-128.
  10. Борисов И.А., Сура В.В., Попова Л.А. и др. К проблеме нефритов пожилого и старческого возраста. Тер. архив. 1995; 6: 5-9.
  11. Preston R.A., Stemmer C.L., Materson B.J. et al. Renal biopsy in patients 65 years of age or older. An analysis of the results of 334 biopsies. J. Am. Geriatr. Soc. 1990; 38: 669-674.
  12. Rychlik I., Jancova E., Tesar V. et al. The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000. Nephrol. Dial. Transplant. 2004; 19: 3040-3049.
  13. Rivera F., Lopez-Gomez J.M., Perez-Garcia R. Clinicopathologic correlations of renal pathology in Spain. Kidney Int. 2004; 66: 898-904.
  14. Colombo V., Confalonieri R., Minola E. et al. Renal biopsies in the elderly. Contrib. Nephrol. 1993; 105: 102-106.
  15. Cameron J.S. Nephrotic syndrome in the elderly. Semin. Nephrol. 16: 319-329.
  16. Vendemia F., Gesualdo L., Schena F.P. et al. Epidemiology of primary glomerulonephritis in the elderly. Report from the Italian Registry of Renal Biopsy. J. Nephrol. 2001; 14: 340-352.
  17. Мухин Н.А., Хасабов Н.Н., Невраева О.Г. Паранеопластическое поражение почек. Тер. архив. 1986; 8: 111-115.
  18. Мухин Н.А., Хасабов Н.Н., Дзгоева Ф.У. Паранеопластический амилоидоз. Тер. архив. 1980; 4: 95-97.
  19. Козловская Л.В., Туганбекова С.К., Сейсембеков Т.З. Паранеопластическое поражение почек при солидных опухолях. Нефрология и диализ. 2002; 4(2): 76-81.
  20. Lin F.C., Chen J.Y., Yang A.H. et al. The association of non-small-cell lung cancer, focal segmental glomerulosclerosis, and platelet dysfunction. Am. J. Med. Sci. 2002; 324: 161-165.
  21. Schillinger F., Milcent T., Wolf C. et al. Nephrotic syndrome revealing malignant thymoma. Presse Med. 1998; 27: 60-63.
  22. Ishida I., Hirakata H., Kanai H. et al. Steroid-resistant nephrotic syndrome associated with malignant thymoma. Clin. Nephrol. 1996; 46: 340-346.
  23. Waki M., Ishimura E., Morii H. et al. A case of membranous glomerulonephritis associated with gastric cancer. Osaka City Med J. 1997; 43: 95-105.
  24. Yahata N., Kawanishi Y., Okabe S. et al. Membranous glomerulonephritis with nephrotic syndrome associated with chronic lymphocytic leukemia. Am. J. Nephrol. 2000; 20: 402-407.
  25. Piccoli G., Rollino C., Vallero A. et al. Glomerulonephritis in the elderly. Minerva Urol. Nefrol. 1996; 48: 7-12.
  26. Couser W.G. Glomerulonephritis Lancet 1999; 353: 1509-1515.
  27. Rydel J.J., Korbet S.M., Borok R.Z., Schwartz M.M. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am. J. Kidney Dis. 1995; 25: 534-542.
  28. Norris M., Kissel C., Roy L. Minimal change glomerulonephritis in a 90-year-old patient: what is the ideal approach? Nephron. 1996; 73: 670-673.
  29. Donadio J.V. Treatment of glomerulonephritis in the elderly. Am. J. Kidney Dis. 1990; 16: 307-311.
  30. Simon P., Ramee M.-P., Boulahrouz R. et al. Epidemilogic data of primary glomerular disease in western France. Kidney Int. 2004; 66: 905-908.
  31. Washio M., Oh Y., Okuda S. et al. Clinicopathological study of poststreptococcal glomerulonephritis in the elderly. Clin. Nephrol. 1994; 41: 265-270.
  32. Lui S.L., Chan K.W., Yip P.S. et al. Simultaneous occurrence of diabetic glomerulosclerosis, IgA nephropathy, crescentic glomerulonephritis, and myeloperoxidase-antineutrophil cytoplasmic antibody seropositivity in a Chinese patient. Am. J. Kidney Dis. 2002; 40: E14.
  33. Ninomiya T., Kanai H., Hirakawa M. et al. Myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritis superimposed on biopsy-proven diabetic nephrosclerosis. Am. J. Kidney Dis. 2002; 39: E4.
  34. Higgins R.M., Goldsmith D.J.A., Counnolly J. et al. Vasculitis and rapidly progressive glomerulonephritis in the elderly. Postgrad. Med. J. 1996; 72: 41-44.
  35. Nakajima H., Miyazaki M., Imai N. et al. A case of silicosis with MPO-ANCA-associated glomerulonephritis and alveolar hemorrhage. Nippon Jinzo Gakkai Shi. 2001; 43: 351-356.
  36. Борисов И.А., Сура В.В., Грибунов Ю.П. Пиелонефрит в старческом возрасте. Тер. архив. 1983; 6: 3-9.
  37. Ulinski T., Bensman A. Renal complications of non-steroidal anti-inflammatories. Arch. Pediatr. 2004; 11: 885-888.
  38. Noels I.M., Elseviers M.M., DeBroe M.E. Impact of legislative measures on the sales of analgetics and the subsequent prevalence of analgesic nephropathy: a comparative study in France, Sweden and Belgium. Nephrol. Dial. Transplant. 1995; 10: 167-174.
  39. DeBroe M.E., Elseviers M.M., Bengtsson U. et al. Analgesic nephropathy. Nephrol. Dial. Transplant. 1996; 11: 2407-2408.
  40. Henrich W.L. Analgesic nephropathy. Am. J. Kidney Dis. 1996; 28 (Suppl. 1): S1-S70.
  41. Duggin C.G. Combination analgesic-induced kidney disease: the Australian experience. Am. J. Kidney Dis. 1996; 28 (Suppl. 1): S39-S47.
  42. Matousovic K., Elseviers M.M., Devecka D. et al. Incidence of analgesic nephropathy among patients undergoing renal replacement therapy in the Czech republic and Slovak republic. Nephrol. Dial. Transplant. 1996; 11: 1048-1051.
  43. Pinter I., Matyus J., Czegany Z. et al. Analgesic nephropathy in Hungary: the HANS study. Nephrol. Dial. Transplant. 2004; 19: 840-843.
  44. Тареева И.Е., Андросова С.О. Влияние ненаркотических анальгетиков и нестероидных противовоспалительных препаратов на почки. Тер. архив. 1999; 6: 17-21.
  45. Perneger T.V., Whelton P.K., Klag M.J. Risk of kidney failure associated with the use of acetaminophen, aspirin and nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 1994; 331: 1675-1679.
  46. Palmer B.F. Renal complications associated with use of nonsteroidal anti-inflammatory agents. J. Invest. Med. 1995; 43: 516-533.
  47. Komers R., Anderson S., Epstein M. Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. Am. J. Kidney Dis. 2001; 38: 1145-1157.
  48. Brunner F.P., Selwood N.H. End-stage renal disease due to analgesic nephropathy, its changing pattern and cardiovascular mortality. Nephrol. Dial. Transplant. 1994; 9: 1371-1376.
  49. Weber M., Braun B., Kohler H. Ultrasonic findings in analgesic nephropathy. Nephron 1985; 39: 216-222.
  50. Elseviers M.M., De Broe M.E. High diagnostic performance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure. Kidney Int. 1995; 48: 1316-1323.
  51. Мухин Н.А. Профилактическая нефрология и образ жизни современного человека. Тер. архив. 1993; 6: 4-7.
  52. Grimaldi A., Grange V., Allannic H. et al. Epidemiological analysis of patients with Type 2 diabetes in France. J. Diabetes Complications. 2000; 14: 242-249.
  53. Ritz E., Orth S.R., Nephropathy in patients with type 2 diabetes mellitus. N. Engl. J. Med. 1999;341: 1127-1133.
  54. Remuzzi G., Schiepatti A., Ruggenenti P. Nephropathy in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2002; 346: 1145-1151.
  55. Opie L.H., Parving H.-H. Diabetic nephropathy. Can renoprotection be extrapolated to cardiovascular protection? Circulation 2002; 106: 643-645.
  56. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001; 345: 851-860.
  57. Brenner B.M., Cooper M.E., de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345: 861-869.
  58. Гордеев А.В., Песков Д.Ю. Гетерогенность причин протеинурии у больных инсулиннезависимым сахарным диабетом. Тер. архив. 2001; 6: 51-54.
  59. Balal M., Paydas S., Seyrek N. et al. Other glomerular pathologies in three patients with diabetes mellitus. Ren. Fail. 2004; 26: 185-188.
  60. Courreges J.P., Bacha J., Aboud E. Prevalence and profile of renovascular disease in type II diabetic patients with severe hypertension. Arch. Mal. Coeur Vaiss. 1997; 90: 1059-1063.
  61. Фомин В.В., Моисеев С.В., Швецов М.Ю. и др. Ишемическая болезнь почек и сочетанные хронические нефропатии: клинические и прогностические особенности. Тер. архив. 2007; 6: 44-49.
  62. Alcasar J.M., Marin R., Gomez-Campdera F. et al. Clinical charasteristics of ischaemic renal disease. Nephrol. Dial. Transplant. 2001; 16 (Suppl. 1): 74-77.
  63. Wynckel A., Ebikili B., Melin J.P. et al. Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors. Am. J. Hypertens. 1998; 11: 1080-1086.
  64. Kuroda S., Nishida N., Uzu T. et al. Prevalence if renal artery stenosis in autopsy patients with stroke. Stroke 2000; 31: 61-65.
  65. Pedersen E.B. New tools in diagnosing renal artery stenosis. Kidney Int. 2000; 57: 2657-2677.
  66. Ramos F., Kotliar C., Alvarez D. et al. Renal function and outcome of PTRA and stenting for atherosclerotic renal artery stenosis. Kidney Int. 2003; 63: 276-282.
  67. Zanchetti A., Bold G., Hennig M. et al. Calcium antagonist lacidipin slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-2427.
  68. Johansson M., Herlitz H., Jensen G. et al. Increased cardiovascular mortality in hypertensive patients with renal artery stenosis. Relation to sympathetic activation, renal function and treatment regimens. J. Hypertens. 1999; 17: 1743-1750.
  69. Fatica R.A., Port F.K., Young E.W. Incidence trends and mortality in end-stage renal disease attributed to renovascular disease in the United States. Am. J. Kidney Dis. 2001; 37: 1184-1190.
  70. Textor S.C. Atherosclerotic renovascular disease as a cause of end-stage renal disease: cost considerations. Blood Purif. 1996; 14: 305-314.
  71. Klag M.J., Whelton P.K., Randall B.L. et al. End-stage renal disease in African-American and white men: 16-year MRFIT findings. J.A.M.A. 1997; 277: 1293-1298.
  72. Luft F.C. Hypertensive nephrosclerosis - a cause of end-stage renal disease? Nephrol. Dial. Transplant. 2000; 15: 1515-1517.
  73. Mazzali M., Hughes J., Kim Y.-H. et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106.
  74. Мухин Н.А., Шоничев Д.Г., Балкаров И.М. и др. Формирование артериальной гипертонии при уратном тубулоинтерстициальной поражении почек. Тер. архив. 1999; 6: 12-24.
  75. Dikow R., Zeier M., Ritz E. Cardiovascular abnormalities and hypertension in the elderly dialysis patient. Semin. Dial. 2002; 15: 121-126.
  76. Alloatti S., Manes M., Gaiter A.M. et al. Dialysis in the elderly. G. Ital. Nefrol. 2002; 19: 622-629.
  77. Letourneau I., Ouimet D., Dumont M. et al. Renal replacement in end-stage renal disease patients over 75 years old. Am. J. Nephrol. 2003; 23: 71-77.
  78. Orth S.R. Smoking - a renal risk factor. Nephron 2000; 86: 12-26.
  79. Whelton P.K., Appel L.J., Espeland M.A. et al. Sodium restriction and weight loss in the treatment of hypertension in older persons. A randomized controlled trial of non-pharmacological interventions in the elderly (TONE). J.A.M.A. 1998; 279: 839-846.
  80. O'Hare A.M., Choi A.I., Bertenthal D. et al. Age affects outcomes in chronic kidney disease. J. Am. Soc. Nephrol. 2007; 18(10): 2758-2765.
  81. Shlipak M.G., Katz R., Fried L.F. et al. Cystatin-C and mortality in elderly persons with heart failure. J. Am. Coll. Cardiol. 2005; 45(2): 268-271.
  82. Menon V., Shlipak M.G., Wang X. et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann. Intern. Med. 2007; 147(1): 19-27.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies